| Detected | Trial | Change |
|---|---|---|
| 2026-05-29 | NCT03312400 Low-Dose Danazol for the Treatment of Telomere Related Diseases |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-05-29 | NCT03312400 Low-Dose Danazol for the Treatment of Telomere Related Diseases |
Enrollment reduced: 40 -> 18 participants |
| 2026-05-16 | NCT03312400 Low-Dose Danazol for the Treatment of Telomere Related Diseases |
date change Primary completion pushed: 2026-04-29 -> 2027-04-29 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-01 | NCT07616154 Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease | Phase 2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06526117 | Stroke Prevention in Nigeria 2 Trial | Sickle Cell Disease | Recruiting |
| Phase 3 | |||
| NCT06093672 | Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With… | Polycythemia Vera | Recruiting |
| NCT04116502 | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in… | Polycythemia Vera | Recruiting |
| NCT06456346 | Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | Essential Thrombocythemia | Recruiting |
| NCT03165734 | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia… | Primary Myelofibrosis | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT03373968 | Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study | Duchenne Muscular Dystrophy | Recruiting |
| Phase 2 | |||
| NCT07033598 | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | Leukemia, Myelomonocytic, Chronic | Recruiting |
| NCT06930352 | Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute… | Acute Myeloid Leukemia | Not Yet Recruiting |
| NCT07507760 | Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients | Acute Myeloid Leukemia With Gene Mutations | Not Yet Recruiting |
| NCT06171217 | Realizing Effectiveness Across Continents With Hydroxyurea | Sickle Cell Disease | Active, Not Recruiting |
| NCT07616154 | Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease | Sickle Cell Disease | Not Yet Recruiting |
| NCT03312400 | Low-Dose Danazol for the Treatment of Telomere Related Diseases | Telomere Disease | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT03500731 | Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure | Idiopathic Pulmonary Fibrosis | Recruiting |
| NCT05357482 | Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell… | Sickle Cell Anemia | Active, Not Recruiting |
| NCT03077542 | Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell… | Sickle Cell Disease | Active, Not Recruiting |
| Phase 1 | |||
| NCT05526924 | Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With… | Head and Neck Cancer | Recruiting |
| NCT07190833 | A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory… | Treatment-Refractory Solid Tumors | Recruiting |
| NCT06871410 | Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or… | Recurrent Acute Myeloid Leukemia | Recruiting |
| NCT07170592 | A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory… | Treatment-Refractory Solid Tumors | Not Yet Recruiting |
| Early Phase 1 | |||
| NCT05662098 | Alternative Dosing And Prevention of Transfusions (ADAPT) | Sickle Cell Disease | Active, Not Recruiting |
| Not specified | |||
| NCT03511118 | Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed… | Lactating Women on Select DOI | Recruiting |
| NCT04217356 | Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis | Myelofibrosis | Active, Not Recruiting |
| NCT07543289 | Hydroxyurea Optimisation in Sickle Cell Disease | Sickle Cell Disease | Not Yet Recruiting |